This new Project 3 in the UPCI Lung Cancer SPORE builds on both clinical and population based resource development and substantive research findings from the prior SPORE funding periods. Project 3 will pursue three translational aims to refine and validate a lung cancer risk prediction model and a diagnostic serum biomarker panel.
In Specific Aim 1, Project 3 will construct a genetic risk index from single nucleotide polymorphism (SNP) genotype information, measure the index's association with lung cancer (Aim 1 A), and evaluate the index's contribution to our published lung cancer prediction model that incorporates demographic, cigarette smoking exposure, and clinical variables (Aim 1B).
In Specific Aim 2, Project 3 will evaluate the lung cancer discrimination performance of a promising lung cancer diagnostic rule model constructed from the serum concentrations of 10 biomarker proteins (Aim 2A) and verify its performance in subjects with intermediate suspicion pulmonary nodules on screening computerized tomography (CT) (Aim 2B) and diagnostic performance independent of demographic, smoking, clinical, and genetic variables (Aim 2C).
These aims use shared lung cancer cases (n=180) emerging from the Pittsburgh Lung Screening Study (PLuSS), a comparable lung cancer case series (n=548) derived from clinical sources, and controls [n=993 (Aim 2A) or n=482 (Aim 2B)] sampled from the PLuSS cohort. Collaboration with the Biostatistics and Bioinformatics Core will develop improved models based on these expansive datasets. A concluding translational aim uses independent comparison groups from the ACRIN/NLST and ACOSOG Z4031 cohorts to validate these prediction and diagnostic strategies (Aim 3). Completion of Aim 1 will produce a lung cancer risk prediction model that capably selects individuals for primary chemoprevention or enhanced screening.
Aim 2 will yield a lung cancer diagnostic test to improve early lung cancer detection in the contexts of clinical trials of primary chemoprevention and management of high-risk subjects with CT-detected nodules. Lastly, Aim 3 will evaluate the performance of both the lung cancer prediction and diagnostic models in two large and similar case-control cohorts for independent validation and refinement of the final models.

Public Health Relevance

Project 3 will improve prediction of lung cancer risk among the tobacco-exposed population by using genetic variation in combination with previously identified risk factors. Project 3 will also verify and refine a noninvasive blood-based lung cancer diagnostic test that could be applied to lung cancer diagnosis in very high risk groups and to clinical management of CT-detected lung nodules of uncertain malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-12
Application #
8555305
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2001-06-01
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$318,815
Indirect Cost
$108,376
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. Mol Cancer Ther 16:793-804
Moiseeva, Tatiana; Hood, Brian; Schamus, Sandy et al. (2017) ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun 8:1392
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. Mol Cancer Ther 16:1658-1668
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Murine Bronchoalveolar Lavage. Bio Protoc 7:
Yochum, Zachary A; Cades, Jessica; Mazzacurati, Lucia et al. (2017) A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res 15:1764-1776
Zhou, Jingjiao; Qu, Zhaoxia; Sun, Fan et al. (2017) Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation. Cancer Immunol Res 5:257-268

Showing the most recent 10 out of 183 publications